The market is a chaotic place, and nothing proves it more than this week's random assortment of corporate survivors, biotech dreamers, and walking dead. We've got Wall Street predators sharing space with bankrupt solar plays. This is stupid and here's why: pretending all these businesses deserve the same attention span is a delusion. But since we are here, let's separate the wheat from the absolute chaff.

The Grown-Ups in the Room

Let's start with the few actually making money. JPMorgan Chase (JPM-D.US) is sitting on a casual USD 5.0T in assets as of June 2026. Jamie Dimon's empire is throwing off preferred stock dividends while everyone else is scrambling. Then you have Trane Technologies (TT.US), which is quietly crushing it. They posted USD 4.97B in Q2 2026 revenue, up 6.0%. Instead of selling AI vaporware, they bought LiquidStack in February to actually cool down the servers everyone is buying. That is a smart play.

Asleep at the Wheel

Then we have the consumer discretionary dump. Tripadvisor (TRIP.US) managed to offload TheFork to Amex for USD 700M in June 2026. Good for them, because their core business missed Q2 estimates at USD 382.4M in revenue. It is 2026, and they still lack a cohesive identity. Good luck with that.

Funko (FNKO.US) and Rocky Mountain Chocolate Factory (RMCF.US) are acting like it's still 2021. Funko's 2025 revenue slumped to USD 908M, and they just pushed their credit deadline to late 2027 to stay afloat. Meanwhile, RMCF is bleeding USD 1.2M in Q1 FY2027 while playing musical chairs with interim CEOs. Why aren't you moving faster to fix this?

Miners and Cash Burners

In the dirt-digging department, BHP Group (BHPLF.US) is dealing with a massive July 2026 strike at Port Hedland, freezing USD 80M a day in iron ore exports. Conversely, Avino Silver & Gold Mines (ASM.US) is minting cash, with a record USD 39.4M in Q1 2026 revenue.

As for the biotech lottery tickets—Immutep (IMSR.US) and aTyr Pharma (ATYR.US)—it's the same old cash burn. Immutep had to halt a Phase III lung cancer trial in March for futility before pivoting to hype some July combination therapy data. aTyr is still plugging away at its Efzofitimod trials. I'll care when the FDA cares.

Finally, there's Maxeon Solar Technologies (MAXNQ.US). Placed under judicial management in Singapore in April 2026, their H1 2025 revenue collapsed to USD 39M. Relying on a supply chain that gets you blocked by US Customs was a fatal error. Game over.

This article does not constitute investment advice.